Sep 19 2026 02:29 AM EST

Sep 19 2026 00:00 EST

Exact Sciences, Illumina and Zscaler Lead Gains as EchoStar, Arrowhead and Ball Falter

Exact Sciences (NASDAQ:EXAS) surged 26% after reporting double‑digit Q2 revenue growth and raising its 2026 outlook, while Zscaler (NASDAQ:ZS) climbed 18.4% on an earnings beat and AI‑security momentum. Illumina (NASDAQ:ILMN) added roughly 7% on strong Q2 results and an upcoming S&P 500 inclusion. In contrast, EchoStar (NASDAQ:ECHO) fell 23.9% amid a $2.4 billion FCC escrow requirement and looming debt maturities, Arrowhead Pharmaceuticals (NASDAQ:ARWR) dropped 18.1% after interim data missed expectations and heightened rate concerns, and Ball Corporation (NYSE:BLL) slipped 15.4% as operating margins compressed and North‑American capacity constraints limited sales.

Exact Sciences posted Q2 revenue growth of “double‑digit YoY” and raised its 2026 guidance to $3.07 billion‑$3.12 billion, adding roughly $40 million to the prior outlook. The Abbott Laboratories acquisition, valued at about $21 billion in equity, is slated to close on March 23 2026 at a premium of $105 per share. Zscaler reported Q4 FY26 revenue of $898.2 million (up 25% YoY) and adjusted EPS of $1.19, beating estimates and prompting FY27 revenue guidance of $3.91–$3.94 billion. Illumina’s Q2 revenue of $1.16 billion rose 9.5% YoY, with non‑GAAP EPS of $1.31 beating consensus; the company lifted full‑year 2026 revenue guidance to $4.60‑$4.64 billion. EchoStar’s Q2 revenue slipped 4% YoY to $3.58 billion, while a non‑cash deconsolidation gain of $9.73 billion inflated net income to $8.46 billion. Arrowhead reported Q2 revenue of $73.7 million, a steep decline from the prior year, and a net loss of $132.7 million. Ball posted Q2 revenue of $3.997 billion (up 19.7% YoY) but operating margin fell to 8.7% from 10.3% a year earlier.

Exact Sciences Leads the Rally

The 26% gain reflects investor confidence in the company’s expanding colorectal‑cancer screening franchise. Double‑digit top‑line growth was driven by the Cologuard stool‑based test and the multi‑cancer blood assay Cancerguard, while adjusted EBITDA improved, narrowing the net loss. Management’s modest upward revision of 2026 revenue guidance, coupled with the imminent Abbott acquisition at a premium that mirrors the current share price of $104.91, reinforced the perception of a near‑term value‑capture event. Analyst consensus targets the stock near $98.21, with a fair‑value estimate of $105.81, suggesting the rally may be a re‑pricing of growth expectations.

Illumina Gains on Earnings Beat and Index Inclusion

Illumina’s 7% rise was anchored by a 9.5% YoY revenue increase to $1.16 billion and a non‑GAAP EPS of $1.31, surpassing consensus. Strong demand for NovaSeq X instruments—accounting for 83% of instrument volume—propelled a 31% jump in instrument revenue and a 15% rise in clinical consumables. The company also announced its upcoming inclusion in the S&P 500 on September 21, a catalyst that typically triggers passive‑flow buying. Guidance was lifted to a 2026 revenue range of $4.60‑$4.64 billion and non‑GAAP EPS of $5.30‑$5.40, reinforcing growth expectations.

Zscaler Benefits from AI‑Security Momentum

The 18.4% rally followed a Q4 FY26 earnings beat that delivered revenue of $898.2 million and adjusted EPS of $1.19, exceeding the consensus of $1.09. Management highlighted a 50% sequential increase in “security for AI” bookings and a 75% rise in the AI‑security pipeline, underscoring growing demand for the company’s zero‑trust and AI‑driven offerings. FY27 guidance of $3.91–$3.94 billion revenue (16–17% YoY growth) and ARR of $4.40–$4.43 billion positioned the stock as a relatively cheap cloud‑security play, with an average price target of $207.

EchoStar Slides on Liquidity and Debt Maturities

EchoStar’s 23.9% decline reflects heightened liquidity concerns. The FCC‑mandated escrow of $2.4 billion for the AT&T spectrum sale, combined with long‑term debt exceeding $18 billion and cash of only $1.55 billion, compresses the balance sheet. A $1.5 billion Hughes debt maturity on August 1 2026, with merely $102 million of cash on hand, adds immediate refinancing risk. Although Q2 earnings featured a non‑cash deconsolidation gain of $9.73 billion, excluding that item would leave net income at roughly $49.5 million, underscoring the underlying profitability challenge.

Arrowhead Falls After Interim Data Miss and Rate Sensitivity

Arrowhead’s 18.1% slide was triggered by interim topline results for ARO‑DIMER‑PA that fell short of consensus expectations. While mean maximal reductions of 72% (PCSK9) and 88% (APOC3) were reported, LDL‑C fell 54%—below analyst forecasts for a first‑in‑class launch. The company posted Q2 revenue of $73.7 million, a 3.4% beat versus the consensus of $71.5 million but a 9.6% miss against higher internal estimates. Net loss widened to $132.7 million. The broader biotech sell‑off was amplified by the Federal Open Market Committee’s indication of a possible rate hike, pushing 10‑year Treasury yields above 5 % and depressing growth‑stock multiples.

Ball Declines Amid Margin Compression and Capacity Constraints

Ball’s 15.4% five‑day decline reflects investor focus on eroding profitability. Revenue rose 19.7% YoY to $3.997 billion, beating estimates, but operating margin slipped to 8.7% from 10.3% a year earlier. Management cited “notably tight” capacity in the North & Central America segment, which posted comparable operating earnings of $207 million on sales of $2.00 billion—a 2.4% YoY decline. The start‑up costs of the new Millersburg, Oregon plant added approximately $5 million in Q2, with full‑year expenses projected near $35 million. Spot aluminum prices of $3,500‑$3,600 per metric ton, driven by geopolitical tensions, further increase input‑cost uncertainty.

Sector Themes and Outlook

The divergent moves illustrate two broader market currents. In the technology and health‑care space, strong earnings, progressive guidance, and strategic milestones (Acquisition progress, AI‑security demand, S&P 500 inclusion) are rewarding firms that demonstrate operating leverage and clear growth pathways. Conversely, companies facing liquidity constraints, heightened debt maturities, or macro‑sensitive cost structures—particularly in satellite broadband, biotech, and aluminum‑packaging—are penalized as investors prioritize balance‑sheet resilience amid rising rates and geopolitical volatility. The five‑day performance suggests capital is rotating toward firms with near‑term earnings visibility while remaining wary of entities with significant near‑term cash‑flow or refinancing risks.